Select Equity Group L.P. Has $104.58 Million Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Select Equity Group L.P. lowered its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 21.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 201,019 shares of the medical research company's stock after selling 55,366 shares during the period. Select Equity Group L.P. owned about 0.05% of Thermo Fisher Scientific worth $104,576,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of TMO. Barrett & Company Inc. bought a new stake in Thermo Fisher Scientific during the fourth quarter worth approximately $28,000. FPC Investment Advisory Inc. bought a new stake in Thermo Fisher Scientific during the fourth quarter worth approximately $28,000. Missouri Trust & Investment Co bought a new stake in Thermo Fisher Scientific during the fourth quarter worth approximately $29,000. Pillar Financial Advisors LLC bought a new stake in Thermo Fisher Scientific during the fourth quarter worth approximately $29,000. Finally, Endeavor Private Wealth Inc. bought a new stake in Thermo Fisher Scientific during the fourth quarter worth approximately $30,000. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock traded down $0.45 during midday trading on Tuesday, reaching $413.47. The company's stock had a trading volume of 2,141,884 shares, compared to its average volume of 1,845,527. Thermo Fisher Scientific Inc. has a fifty-two week low of $390.50 and a fifty-two week high of $627.88. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The stock's 50 day simple moving average is $451.89 and its 200 day simple moving average is $508.88. The firm has a market capitalization of $156.08 billion, a PE ratio of 25.01, a P/E/G ratio of 2.99 and a beta of 0.82.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The firm had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. During the same quarter in the previous year, the company posted $5.11 EPS. The firm's revenue for the quarter was up .2% on a year-over-year basis. On average, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were issued a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.42%. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. Thermo Fisher Scientific's payout ratio is presently 10.09%.

Insider Transactions at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 3,775 shares of the firm's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the transaction, the senior vice president now directly owns 10,816 shares of the company's stock, valued at approximately $5,759,736.32. This trade represents a 25.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total value of $5,166,700.00. Following the transaction, the chief executive officer now directly owns 115,174 shares in the company, valued at approximately $59,506,950.58. The trade was a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 14,075 shares of company stock worth $7,305,942. 0.33% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on TMO shares. Evercore ISI cut their target price on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. Morgan Stanley increased their target price on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an "overweight" rating in a research report on Friday, January 31st. Stifel Nicolaus cut their target price on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a research report on Thursday, April 24th. The Goldman Sachs Group set a $610.00 target price on shares of Thermo Fisher Scientific and gave the stock a "buy" rating in a research report on Wednesday, April 23rd. Finally, UBS Group reduced their price objective on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating for the company in a research note on Thursday, April 24th. Five equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific currently has an average rating of "Moderate Buy" and an average target price of $607.43.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.